Table 2.
Methylation of DDR and related genes in cancers
| Pathway | gene | tumor type | methylation frequency | refs |
|---|---|---|---|---|
| DDR | BRCA1 | pancreatic | 46% | [149] |
| NSCLC | 30% | [129] | ||
| ESCC | 28% | [110] | ||
| ovarian | 16.3% | [150] | ||
| BRCA2 | NSCLC | 42% | [129] | |
| MGMT | gliomas | 40% | [130] | |
| NSCLC | 30% | [142] | ||
| gastric | 9.8% | [122] | ||
| MLH1 | CRC | 38% | [151] | |
| ESCC | 33% | [110] | ||
| gastric | 21.6% | [122] | ||
| MSH2 | HPNCC | 24% | [152] | |
| HCC | 24.6% | [153] | ||
| WRN | CRC | 37.9% | [118] | |
| NSCLC | 37.5% | [118] | ||
| gastric | 25% | [118] | ||
| prostate | 20% | [118] | ||
| FANCF | cervical | 30% | [154] | |
| ovarian | 21% | [154] | ||
| breast | 17% | [154] | ||
| DDR related | P16 | ESCC | 52% | [110] |
| NSCLC | 29% | [142] | ||
| CHFR | ESCC | 45% | [141] | |
| gastric | 34.3% | [122] | ||
| NSCLC | 10% | [142] | ||
| RASSF1A | gliomas | 79.4% | [155] | |
| cholangiocarcinoma | 65% | [156] | ||
| gastric | 12.7% | [122] | ||
| SLFN11 | CRC | 55.47% | [120] | |
| papillary serous ovarian | 39% | [119] | ||
| gastric | 29.9% | [121] | ||
| NSCLCs. | 13.6% | [119] | ||
| DACT2 | ESCC | 69% | [145] | |
| gastric | 55.7% | [157] | ||
| breast | 49.7% | [146] | ||
| lung | 41% | [144] | ||
| NKD2 | ESCC | 53.2% | [148] | |
| gastric | 53.1% | [158] | ||
| breast | 51.4% | [159] | ||
| HIN-1 | ESCC | 50% | [160] | |
| NSCLC | 48% | [161] | ||
| DACH1 | gastric | 63.3% | [162] | |
| ESCC | 61.5% | [163] | ||
| HCC | 42% | [164] |
NSCLC Non-small cell lung cancer, ESCC Esophageal squamous cell carcinoma, CRC Colorectal cancer, HPNCC Hereditary non-polyposis, HCC Hepatocellular carcinoma